Overview

Iron bisglycinate (ferrous bisglycinate chelate) is a form of supplemental iron in which a ferrous (Fe²⁺) ion is chelated — covalently bound — to two molecules of the amino acid glycine, forming a stable, neutral complex with a low molecular weight of approximately 204 Da. This chelation structure protects the iron from interactions with dietary inhibitors (phytates, polyphenols, calcium, and fiber) in the gastrointestinal tract, as the iron-glycine complex is absorbed intact through dipeptide transporters (PepT1) on enterocytes rather than relying solely on the divalent metal transporter 1 (DMT1) pathway used by ionic iron salts. This dual absorption mechanism results in significantly higher bioavailability — studies demonstrate 2–4 times greater absorption compared to ferrous sulfate on a milligram-for-milligram basis.

The clinical advantages of iron bisglycinate extend beyond absorption efficiency. Because the iron remains chelated through the gastric environment, it does not generate free ferrous ions that catalyze Fenton reactions and produce reactive oxygen species in the intestinal mucosa — the primary mechanism behind the nausea, cramping, constipation, and dark stools commonly experienced with ferrous sulfate and ferrous fumarate. Multiple randomized controlled trials in pregnant women, children, and adults with iron deficiency anemia have confirmed that iron bisglycinate achieves equivalent or superior increases in hemoglobin and ferritin levels at lower elemental iron doses (typically 25–50 mg elemental iron versus 60–120 mg with ferrous sulfate) while producing significantly fewer gastrointestinal adverse effects and better adherence.

Iron bisglycinate is recommended as a first-line supplemental form for individuals with iron deficiency who are intolerant of conventional iron salts, as well as for populations requiring long-term supplementation such as pregnant women, menstruating women, and endurance athletes. It can be taken with meals without the typical reduction in absorption seen with ionic iron forms, offering greater flexibility in dosing. Co-supplementation with vitamin-c further enhances absorption, while lactoferrin may provide synergistic iron delivery through its own receptor-mediated uptake pathway. The glycine component itself has calming neurotransmitter properties and supports collagen synthesis, adding modest ancillary benefits. Iron status should be monitored through ferritin and transferrin saturation to guide dosing, as even well-tolerated forms should not be supplemented without confirmed deficiency due to the risks of iron overload.

Mechanism of Action

Iron Bisglycinate (ferrous bisglycinate chelate) is an iron supplement in which a ferrous iron (Fe2+) ion is chelated between two molecules of the amino acid glycine, forming a stable double-amino acid chelate ring structure. This chelation fundamentally alters how iron is absorbed compared to conventional iron salts like ferrous sulfate. The bisglycinate chelate is absorbed intact through the intestinal mucosa via peptide transport pathways (PepT1 and related dipeptide transporters) rather than exclusively through the conventional DMT1 (divalent metal transporter 1) pathway used by ionic iron. This dual absorption mechanism provides significantly higher bioavailability while bypassing many of the factors that typically inhibit iron absorption, including phytates, tannins, calcium, and other dietary chelators.

Once absorbed, iron from bisglycinate enters the same systemic iron metabolism as any other iron source. In enterocytes, iron is released from the glycine chelate and either stored as ferritin or exported across the basolateral membrane via ferroportin into the plasma. In circulation, iron binds to transferrin and is transported to target tissues. The primary therapeutic effect stems from replenishing iron stores and supporting hemoglobin synthesis in erythroid precursor cells. Iron is incorporated into protoporphyrin IX by the enzyme ferrochelatase in mitochondria, forming heme, which combines with globin chains to produce functional hemoglobin. Beyond erythropoiesis, iron serves as a cofactor for numerous enzymes including cytochrome c oxidase (mitochondrial electron transport), ribonucleotide reductase (DNA synthesis), and various cytochrome P450 enzymes.

The glycine chelate structure provides several additional advantages. The neutral charge of the chelate complex reduces the generation of reactive oxygen species in the gut lumen, which is a primary cause of gastrointestinal side effects with conventional iron salts. The chelate also resists precipitation in the alkaline environment of the duodenum, maintaining iron in a soluble, absorbable form. The glycine component itself may provide modest supplementary benefits, as glycine is a precursor to glutathione, an important cellular antioxidant. These combined properties make iron bisglycinate particularly effective for treating iron deficiency anemia with fewer gastrointestinal adverse effects, supporting oxygen transport, cellular energy production, and immune function.

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Iron Bisglycinate

Common Side Effects

• Improved GI tolerability compared to ferrous sulfate: nausea, constipation, and abdominal pain occur significantly less frequently (reported in ~10–15% vs. 30–50% with ferrous sulfate)
• Dark stools (common to all iron supplements; harmless)
• Mild metallic taste (less pronounced than with ferrous sulfate)
• Occasional headache or mild dizziness
• Mild nausea at higher doses

Serious Adverse Effects

• Iron overload: as with any iron supplement, chronic over-supplementation can cause hemosiderosis; bisglycinate's higher bioavailability means lower doses achieve therapeutic effect, but also that accumulation may occur faster if intake is not monitored
• Acute toxicity: though lower-dose formulations reduce risk, pediatric accidental ingestion remains dangerous; toxicity threshold is the same (~20 mg/kg elemental iron)
• Oxidative stress: chelated iron is still bioavailable iron; excess contributes to Fenton chemistry and tissue damage
• Allergic reactions: rare; glycine chelation minimizes but does not eliminate hypersensitivity risk
• GI erosion: significantly less common than with ferrous sulfate, but possible at very high doses

Contraindications

• Hereditary hemochromatosis or any iron-loading disorder
• Active hemolytic anemia without confirmed iron deficiency
• Known allergy to iron bisglycinate or amino acid chelate products
• Iron-replete individuals (supplementation without documented deficiency)
• Active peptic ulcer disease (though bisglycinate is less erosive, caution warranted)

Drug Interactions

• Tetracyclines and fluoroquinolones: chelated iron has REDUCED but not eliminated interaction; still advisable to separate dosing by 2 hours
• Levothyroxine: absorption interference persists with chelated forms; maintain 4-hour separation
• Antacids and PPIs: iron bisglycinate is less affected by gastric pH than ferrous sulfate (absorption via amino acid transporters rather than DMT-1), but some reduction still occurs
• Calcium supplements: competitive absorption interference is reduced compared to non-chelated forms but not eliminated
• Levodopa / methyldopa: separate dosing by 2 hours to prevent chelation

Population-Specific Considerations

• Pregnancy: preferred iron form due to superior tolerability and adherence; effective at lower doses (25–30 mg elemental iron vs. 60–120 mg ferrous sulfate); still requires ferritin monitoring
• Children: better tolerated and available in palatable forms; childproof storage remains critical
• Elderly: excellent choice due to reduced GI side effects and maintained efficacy in low-acid gastric environments (common with aging and PPI use)
• Bariatric surgery patients: bisglycinate's pH-independent absorption pathway makes it preferred post-gastric bypass
• Inflammatory bowel disease patients: significantly less GI irritation; preferred form for iron-deficient IBD patients who cannot tolerate standard iron
• Chronic kidney disease: may be better tolerated orally than ferrous sulfate; still requires nephrologist oversight for dosing

Pharmacokinetic Profile